IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV ‐related and HPV ‐unrelated disease
APMIS · 2024
DOI: 10.1111/apm.13417 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2024. Verfasst von Anni Sjöblom und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Papillomavirus Infections, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Ida Montinin Säätiö, Suomen Hammaslääkäriseura Apollonia.
Abstract (Originalsprache)
Biomarkers are not broadly used in the management of head and neck cancers (HNCs). Biomarkers have been beneficial in the management of other cancers, however, not in HNCs. Therefore, we observed the immunopositivity of a novel biomarker called immunoglobulin superfamily member 3 (IGSF3) in tumor tissues in HPV‐related and HPV‐unrelated OPSCC. Two patient cohorts (C1 and C2) from separate time periods were available for this study (total N = 282). Both consisted of OPSCC patients treated at the Helsinki University Hospital (HUS, Helsinki, Finland) during 2000–2016. For HPV determination, HPV mRNA in situ hybridization was used. Immunohistochemistry was used to assess IGSF3 immunopositivity in cancer tissues. Overall survival (OS) was used as endpoint in the statistical analysis. In C1, stronger immunopositivity of IGSF3 in tumor‐infiltrating lymphocytes (TILs) correlated with favorable OS (p = 0.005). Stronger IGSF3 immunopositivity in tumor cells (TCs) was associated with HPV negativity (p = 0.017). Stronger IGSF3 immunopositivity in TILs correlated with HPV positivity (p < 0.001). Elevated IGSF3 immunopositivity in TILs associates with HPV‐related tumors and may signify favorable prognosis. The immunopositivity of IGSF3 differs between HPV‐related and HPV‐unrelated OPSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Department of Oral Pathology and Oral Radiology, University of Turku, Turku, Finland.
ORCID-Profile: Anni Sjöblom
Förderung
- Wellcome Trust
- Ida Montinin Säätiö
- Suomen Hammaslääkäriseura Apollonia
- Korvatautien Tutkimussäätiö
- Minerva Foundation
- Finnish Cancer Institute
Zitieren
APA
Sjöblom, A., Jouhi, L., Laakkonen, P., Randén-Brady, R., Tarkkanen, J., Haglund, C., Mattila, P., Carpén, T., Hagström, J., & Mäkitie, A. (2024). IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV ‐related and HPV ‐unrelated disease. APMIS. https://doi.org/10.1111/apm.13417
Vancouver
Sjöblom A, Jouhi L, Laakkonen P, Randén-Brady R, Tarkkanen J, Haglund C, et al. IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV ‐related and HPV ‐unrelated disease. APMIS. 2024. doi:10.1111/apm.13417
BibTeX
@article{Sjblom2024,
author = {Sjöblom, Anni and Jouhi, Lauri and Laakkonen, Pirjo and Randén-Brady, Reija and Tarkkanen, Jussi and Haglund, Caj and Mattila, Petri and Carpén, Timo and Hagström, Jaana and Mäkitie, Antti},
title = {IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV ‐related and HPV ‐unrelated disease},
journal = {APMIS},
year = {2024},
doi = {10.1111/apm.13417}
}
EUVIMED